Physician profile
Supreet Singh
NPI 1881275204
$1,343.21
in general payments reported to CMS, 2019-2025
10 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $743 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Education: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.00 |
| Education | $509.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $287.97 | 2024-2025 | Ensite |
| Amgen INC. | $272.62 | 2024-2025 | Repatha |
| Medtronic, INC. | $221.24 | 2024 | Onyx Frontier |
| Pfizer INC. | $208.57 | 2024-2025 | |
| Cleerly, INC. | $150.29 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Regeneron Healthcare Solutions, INC. | $119.59 | 2024 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.34 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $24.50 | 2025 | |
| Boston Scientific Corporation | $21.67 | 2024 | Watchman |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.42 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supreet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.